QNRX vs RANI

Quoin Pharmaceuticals, Ltd. vs Rani Therapeutics Holdings, Inc — Valuation Comparison 2026

QNRX

Biotechnology
Quoin Pharmaceuticals, Ltd.
Quality
2.0
out of 10
Value Trap
Price
$4.94
Last close
Models
6/13
Active
VS

RANI

Biotechnology
Rani Therapeutics Holdings, Inc
Quality
6.0
out of 10
Value Trap
12
SAFE
Price
$0.95
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType QNRX Fair ValueQNRX Upside RANI Fair ValueRANI Upside
Bayesian DCF Intrinsic $1.31 -73.5% $0.20 -79.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.38 -12.4% $0.34 -64.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for QNRX vs RANI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QNRX vs RANI — Which Stock Is More Undervalued?

RANI scores higher with a 6.0/10 quality rating vs QNRX's 2.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Quoin Pharmaceuticals, Ltd. (QNRX) and Rani Therapeutics Holdings, Inc (RANI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QNRX currently trades at $4.94 with a QOC of 2.0/10, while RANI trades at $0.95 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).